Maastricht, Netherlands, May 3, 2017 – Dutch point of care diagnostics solution company FABPulous BV won new patents across the European Union on Wednesday for the unique Integrated Assay Concept behind its CE-marked H-FABP True Rapid Test®, which detects heart attacks within five minutes.
The European Patent Office granted the patent for FABPulous BV’s Integrated Assay Concept in countries across Europe, including Germany, France, the United Kingdom, Italy and the Netherlands. Separate patents for the concept have also been granted to FABPulous by Switzerland and Turkey.
The Integrated Assay Concept patent family is the company’s third alongside patent families for its plasma separation with reagents and its H-FABP Rapid Test technologies.
FABPulous now have 17 granted patents across the three different patent families, which are recognised around the globe; including The Netherlands, the United Kingdom, the United States and China.
“These patents demonstrate the unique nature of the concepts behind our H-FABP True Rapid Test®,” FABPulous Chief Executive Conor O’Brien said.
Current state-of-the-art lateral flow assays on whole blood take 15-20 minutes at minimum to produce a test result and struggle to reach the necessary sensitivity, specificity, or both. The IVD test platform developed by FABPulous allows for a three-fold reduction in the time-to-result, as it produces a test result in 2-5 minutes, coupled with higher precision.
Similarly, molecular diagnostic assays in whole blood samples for targets in plasma may benefit from the reduction of background nucleic acid from blood cells. Sample volume and dilution factors can be adjusted as needed for subsequent testing with any, if not all, technology platforms for plasma derived targets. It can be integrated with a subsequent detection platform or it can prepare intermediary samples for these.
The H-FABP True Rapid Test® was developed by FABPulous under founder and CSO Jan Glatz, Professor of Cardiac Metabolism at the Cardiovascular Research Institute Maastricht (CARIM), Maastricht University as a way for doctors to rule out heart attacks for chest pain sufferers who would otherwise be admitted for observation using the current medical protocols.
For further information please contact:
Conor O’Brien, Chief Executive Officer – email at email@example.com
3029 AK Rotterdam
St John’s Innovation Centre
Cowley Road, Cambridge
CB4 0WS, UK